Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerandomilast in Systemic Sclerosis (SSc)
NCT07497087Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2026
- Primary completion
- Feb 2030
- Modality
- Small Molecules
- Countries
- 45
01
Overview
A Phase 3 trial of nerandomilast in systemic sclerosis (SSc), sponsored by Boehringer Ingelheim. Started Jul 2026; status: recruiting.
02
Drugs
nerandomilast
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07497087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07497087.